Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH

Recruiting now

Conditions studied: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Right Ventricular Function

In brief

The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.

Key facts

Study ID

NCT07667673

Run by

Istanbul University - Cerrahpasa

People needed

50

Starts

2026-05-11

Expected to finish

2027-05-01

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 years or older
• Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines
• Followed at the study center with a diagnosis of PAH
• Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval
• Availability of analyzable clinical, imaging, and hemodynamic data
• Willingness to participate in the study and provision of written informed consent

You may not qualify if…

• Age younger than 18 years
• Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)
• Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval
• Incomplete clinical or imaging data preventing analysis
• Unavailable follow-up data

Where it is running

• Istanbul University Cerrahpasa Institute of Cardiology — Istanbul, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.